InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: NY1972 post# 387

Saturday, 10/22/2016 10:23:40 PM

Saturday, October 22, 2016 10:23:40 PM

Post# of 977
P1 Mayo PI Stephen Ansell:

The key is still to maintain a high cure rate, decrease toxicity, and not compromise this with immunologic changes that could potentially compromise outcomes for patients.

http://www.ascopost.com/issues/august-25-2016/novel-approaches-harness-the-microenvironment-against-hodgkin-lymphoma/